Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2023 call → NOWe need to determine if the transcript describes a defined waiting period the company is currently living through, paying for out of pocket, with a specific near-dated event that ends the wait, and that this is the main current work. Let's examine the transcript. Management discusses several things: Tyvaso DPI royalties, Afrezza, pipeline (MNKD-101, MNKD-201), INHALE-1 and INHALE-3 trials, etc. Key points: They mention "we have people, money, and data" and "we've been waiting for this moment" regarding Afrezza. They talk about INHALE-3 and INHALE-1 data readouts in 2024. They mention "we are at a pivotal inflection point" and "we've been waiting for this moment". They also mention "we have several key value drivers" and "we are just getting started". They talk about "multiple shots on goal". But the question is about a defined waiting period where the company is paying now for something not yet earning, and the end is a specific near-dated event. For example, they mention "we expect to file the R&D here in March and kick off the trial in June" for MNKD-101. They also mention "we'll be studying this in our part one, a single ascending dose as well as our multiple ascending dose" for MNKD-201, with data expected in Q3. They also mention "we have two clinical trials for a present nearing data readouts" (INHALE-1 and INHALE-3). They say "we will wait to see the results of these trials before deciding whether to invest more behind this asset". But is there a specific cost being borne now for something not yet earning? For example, they are funding clinical trials. They mention "we expect to fund much of MNKD-101 and MNKD-201 clinical trial expenses over the next few years through operating cash flow." That is a cost for future benefit. But is it a defined waiting period with a specific near-dated event? Yes, they have timelines for data readouts. However, the question asks: "the company is CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET — that is, does management convey that the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward?" They are paying for clinical trials, which are costs now for future data.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.